ReviewNature reviews. Immunology2022
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases.
Review in Nature reviews. Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.
- Pooled it
- Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.JAMA dermatology · 2026Trial
- A Split-Face Randomized Study on the Efficacy of a Platinum-Liposome-Based Facial Mask Containing Soothing Ingredients for Post-Photorejuvenation Skin Recovery.Journal of cosmetic dermatology · 2025Trial
- Trial
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- SAT1-Induced Spermidine Depletion Potentiates Food Allergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- A transcriptional signature of resting mast cells is associated with improved disease outcome in HRGenes and immunity · 2026Article
- Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review.Diseases (Basel, Switzerland) · 2026Review
- Structural determinants of ligand response specificity in the mast cell activating GPCR, MRGPRX2.The Journal of biological chemistry · 2026Article
- Role of the IRE1α-XBP1 Axis in IgE-Dependent Activation of Mast Cells.International journal of molecular sciences · 2026Article
- Neuroimmune Regulation of Microvascular Inflammation: The Heart-Brain Axis, Mast Cells, and the Protective Role of Flavonoids-A Comprehensive Review.Biomedicines · 2026Review
- Analysis and validation of diagnostic biomarkers and immune cell infiltration characteristics in chronic spontaneous urticaria and autophagy based on machine learning.The World Allergy Organization journal · 2026Article
- Extracellular Vesicles: A Mailcoach From Mast Cell to Other Cell Species.Immunity, inflammation and disease · 2026Review
- Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression.Molecular cancer · 2026Review
- Cell adhesion molecule 1 is upregulated in connective tissue mast cells and potentially contributes in IgE-mediated degranulation.Scientific reports · 2026Article
- Generation of Functionally Competent Human Mast Cells from Limited Blood Volumes.International journal of molecular sciences · 2026Article
- Developmental PBDE exposure persistently impairs mast cell function in vivo and drives sex-specific morphological and transcriptional changes in bone marrow-derived mast cells.Environmental research · 2026Article
- Stromal Cell-Mast Cell Communication Orchestrates Anti-Viral Immunity in the Meninges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single cell transcriptomics analyses reveal functional heterogeneity and anti-tumor role of mast cells in esophageal squamous cell carcinoma.Frontiers in immunology · 2026Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells have crucial roles in allergic and other inflammatory diseases. Preclinical approaches provide circumstantial evidence for mast cell involvement in many diseases, but these studies have major limitations - for example, there is still a lack of suitable mouse models for some mast cell-driven diseases such as urticaria. Some approaches for studying mast cells are invasive or can induce severe reactions, and very few mediators or receptors are specific for mast cells. Recently, several drugs that target human mast cells have been developed. These include monoclonal antibodies and small molecules that can specifically inhibit mast cell degranulation via key receptors (such as FcεRI), that block specific signal transduction pathways involved in mast cell activation (for example, BTK), that silence mast cells via inhibitory receptors (such as Siglec-8) or that reduce mast cell numbers and prevent their differentiation by acting on the mast/stem cell growth factor receptor KIT. In this Review, we discuss the existing and emerging therapies that target mast cells, and we consider how these treatments can help us to understand mast cell functions in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.